Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinosarcoma; Ovarian Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Fallopian Tube Cancer; Fallopian Tube Neoplasms; Primary Peritoneal Carcinoma; Primary Per itoneal Serous Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: TAK228 Sponsors: Imperial College London; Takeda Pharmaceuticals International, Inc.; North Eastern Germany Society of Gynaecologic Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinosarcoma | Endometrial Cancer | Endometrioid Carcinoma | Epithelial Cancer | Fallopian Tube Cancer | Germany Health | OBGYN | Ovarian Cancer | Ovaries | Peritoneal Cancer | Serous Carcinoma